Tuesday, 09. February 2010



The RUBICON Network of Excellence




Our Research




News




Learn About...




Press Releases




Courses and Conferences




Video-Lectures




Meetings




RUBICON Protocols Database




Links




Job Opportunities



Welcome to RUBICON

RUBICON is a “Network of Excellence” funded by the Framework Programme 6 of the European Commission over a five years period (January 2006 – December 2010). It is coordinated by Professor Maria Masucci, Karolinska Institutet, Stockholm, Sweden.

News: LA1 - The Nobel Prize for the discovery of ubiq...


The Nobel Prize in Chemistry 2004 was awarded to Aaron Ciechanover, Avram Hershko and Irwin Rose "for the discovery of ubiquitin-mediated protein d...
» more
News: LA2 - Die Happy? – Live Longer? Or how to manip...


Agnes van Rossum, Karin Hek, Henk Vietor, and Ger Strous UMC Utrecht in collaboration with DDF BV, Bussum, The Netherlands A major topic in tod...
» more
News: LA9 - Monoubiquitination in Endocytosis


Raghunath Peesari and Simona Polo IFOM, Fondazione Istituto FIRC di Oncologia Molecolare Ubiquitin (Ub) is a 76 amino acid residue protein that...
» more
News: LA3 - Pepscan Technology for Fighting Cancer
The idea that the immune system can recognize and respond to tumors was formed in the late 19th century when William Coley, a surgeon at the Memori...
» more
Participant: Maria Masucci's Group


Link: - » more
Participant: Thomas Sommer's Group


The secretory pathway of eukaryotic cells harbors an elaborate protein quality control system, which prevents the accumulation of misfolded or unas...
» more
Participant: DDF Research Group
DDF is involved in several drug discovery programs including finding new cures for prostate cancer, dendritic based cancer vaccines, osteoporosis a...
» more
Participant: Pier Paolo Di Fiore's Group
Our lab has contributed to the characterization of two protein:protein interaction networks, the EH and the mono-ubiquitin (Ub) networks, which pla...
» more
Participant: SME: Proteologics
Proteologics is a biopharmaceutical company comprising bio- and chemi-informatics, target discovery, target validation, assay development and drug...
» more
Participant: CYTOMICS SYSTEMS
CYTOMICS SYSTEMS’ protein degradation approach to drug discovery relies on UbiScreen®, a patented functional screening technology relevant to all t...
» more



SEARCH



»Advanced Search



OVERVIEWS

»Sitemap

»Institutions

»Members



INFOBOX (0/0) show all
Your infobox is empty




Powered by AVERIS